Eli Lilly & Co. vs. Sionna Therapeutics, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| LLY | SION | |
|---|---|---|
| Market Cap | $1.05 trillion | $236.46 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-97,383,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | SION | |
|---|---|---|
| P/E Ratio | 39.15 | — |
| Price / Book | 31.10 | 0.89 |
| Price / Sales | 13.22 | — |
SION leads on 1 of 1 valuation factors.
Profitability
| LLY | SION | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | -36.64% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | SION | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and SION split the dividend factors evenly.
Risk & Sentiment
| LLY | SION | |
|---|---|---|
| Short Interest | 1.29% | 1.39% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SION overview, SION financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.